Cantor Fitzgerald Reiterates Overweight Rating on Arvinas Inc. (ARVN)

Cantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating on Arvinas Inc. (NASDAQ: ARVN).

The analyst commented, "After months of negotiation, Arvinas/Pfizer (PFE, N, covered by C. Gould) announced today (9/17) that they would jointly out-license the ER PROTAC vepdegstrant (vepdeg) to a third party as the conclusion of their 50/50 partnership. Recall that vepdeg has a PDUFA of June 5, 2026 for 2L ESR1m ER+/HER2- metastatic breast cancer (mBC). No economics will be exchanged between Arvinas and Pfizer, and both parties will equally split the economics of the new licensing deal if it comes to fruition."

"This removes a major overhang for Arvinas and should be the first step towards monetizing vepdeg, and a reset of the company. Further cost reduction and $100M share repurchase program should also be a step in the right direction to alleviate concerns on OpEx burn, while returning a portion of cash to shareholders."

For an analyst ratings summary and ratings history on Arvinas Inc. click here. For more ratings news on Arvinas Inc. click here.

Shares of Arvinas Inc. closed at $7.61 yesterday.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
• BofA says CTA Treasury shorts stable, euro short-cover risk rises